Tcr2 Therapeutics Stock Analysis

The latest indifference towards the small price fluctuations of Tcr2 Therapeutics created some momentum for retail investors as it was traded today as low as 0.0 and as high as 0.0 per share. The company management teams did not add any value to Tcr2 Therapeutics investors in June. However, most investors can still diversify their portfolios with Tcr2 Therapeutics to hedge their inherited risk against high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently very low. The very small Stock volatility is a good signal to retail investors with longer-term investment horizons.
Check out World Market Map.

Search Stock Analysis 

 
Refresh
The Tcr2 Therapeutics stock analysis report makes it easy to digest most publicly released information about Tcr2 Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Tcr2 Therapeutics Stock analysis module also helps to analyze the Tcr2 Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Tcr2 Therapeutics Stock Analysis Notes

About 110.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.44. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Tcr2 Therapeutics recorded a loss per share of 2.34. The entity had not issued any dividends in recent years. TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Tcr2 Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 131 people. To find out more about Tcr2 Therapeutics contact Garry Menzel at 617 949 5200 or learn more at http://www.tcr2.com.

Tcr2 Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Tcr2 Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Tcr2 Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Tcr2 Therapeutics is not yet fully synchronised with the market data
Tcr2 Therapeutics has some characteristics of a very speculative penny stock
Net Loss for the year was (73.13 M).
Tcr2 Therapeutics currently holds about 333.28 M in cash with (60.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.73.

Tcr2 Therapeutics Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 504.89 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Tcr2 Therapeutics's market, we take the total number of its shares issued and multiply it by Tcr2 Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (16.85) % which means that it has lost $16.85 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (29.47) %, meaning that it created substantial loss on money invested by shareholders. Tcr2 Therapeutics management efficiency ratios could be used to measure how well tcr2 therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Tcr2 Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tcr2 Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tcr2 Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tcr2 Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Olagunju Peter 3 days ago via Macroaxis 
Acquisition by Olagunju Peter of 286367 shares of Tcr2 Therapeutics subject to Rule 16b-3
Justice Angela over three months ago via Macroaxis 
Exercise or conversion by Justice Angela of 6752 shares of Tcr2 Therapeutics subject to Rule 16b-3
Alfonso Cardama over three months ago via Macroaxis 
Acquisition by Alfonso Cardama of 708 shares of Tcr2 Therapeutics subject to Rule 16b-3
Tomasello Shawn over three months ago via Macroaxis 
Acquisition by Tomasello Shawn of 4177 shares of Tcr2 Therapeutics subject to Rule 16b-3
Robert Hofmeister over six months ago via Macroaxis 
Exercise or conversion by Robert Hofmeister of 7000 shares of TCR2 Therapeutics subject to Rule 16b-3
Somaiya Mayur Ian over six months ago via Macroaxis 
Exercise or conversion by Somaiya Mayur Ian of 2000 shares of TCR2 Therapeutics subject to Rule 16b-3
Hoos Axel over six months ago via Macroaxis 
Acquisition by Hoos Axel of 12100 shares of TCR2 Therapeutics subject to Rule 16b-3
Somaiya Mayur Ian over six months ago via Macroaxis 
Exercise or conversion by Somaiya Mayur Ian of 2000 shares of TCR2 Therapeutics subject to Rule 16b-3
Robert Hofmeister over six months ago via Macroaxis 
Exercise or conversion by Robert Hofmeister of 10002 shares of TCR2 Therapeutics subject to Rule 16b-3
Robert Hofmeister over six months ago via Macroaxis 
Exercise or conversion by Robert Hofmeister of 20000 shares of TCR2 Therapeutics subject to Rule 16b-3
Hoos Axel over a year ago via Macroaxis 
Acquisition by Hoos Axel of 9596 shares of TCR2 Therapeutics subject to Rule 16b-3
Somaiya Mayur Ian over a year ago via Macroaxis 
Acquisition by Somaiya Mayur Ian of 1473 shares of TCR2 Therapeutics subject to Rule 16b-3

Tcr2 Therapeutics Technical and Predictive Indicators

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Tcr2 Therapeutics to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Fund Screener Now

   

Fund Screener

Find activelly-traded funds from around the world traded on over 30 global exchanges
All  Next Launch Module
Check out World Market Map. Note that the Tcr2 Therapeutics information on this page should be used as a complementary analysis to other Tcr2 Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Other Tools for Tcr2 Therapeutics Stock

When running Tcr2 Therapeutics price analysis, check to measure Tcr2 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tcr2 Therapeutics is operating at the current time. Most of Tcr2 Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tcr2 Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Tcr2 Therapeutics' price. Additionally, you may evaluate how the addition of Tcr2 Therapeutics to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Equity Search
Search for activelly traded equities including funds and ETFs from over 30 global markets
Go